Supriya Lifescience Limited
₹846.20-₹22.20 (-2.6%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹5,938 Cr
- P/E
- 32.6x
- EV / EBITDA
- 31.4x
- Revenue
- ₹696 Cr
- Net margin
- 20.9%
- ROCE
- 21.5%
Price chart
Technical chartScreen technicals →+12.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -11.0%
- 3M
- -1.6%
- 6M
- +21.8%
- 1Y
- +12.5%
- 5Y
- +75.0%
52-week range
Day change -₹22.20 (-2.6%) from ₹868 to ₹846 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in SUPRIYA, bought on each weekday since 2022.
AI Summary
Indian StockStrengths1
- Operating margin of 30.9% exceeds Healthcare median (24.8%)
Concerns0
Rule-based from financial data. Not advice.
About the company
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas.
Read moreShow less
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
- Sector
- Healthcare
- Shares outstanding
- 8.0 Cr shares
- ISIN
- INE07RO01027
- BSE code
- 543434
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹5,938 Cr
- P/E
- 32.6x
- P/B
- 5.5x
- EV / EBITDA
- 31.4x
- EV / Sales
- 10.3x
- P/S
- 10.4x
- Earnings yield
- 3.1%
- 52-week high
- ₹1,048.35
- 52-week low
- ₹550.85
Profitability
- Operating margin
- 30.9%
- Net margin
- 20.9%
- EBITDA margin
- 32.8%
- ROE
- 14.6%
- ROCE
- 21.5%
- ROA
- 12.9%
- Dividend payout
- 5.0%
- Tax rate
- 28.0%
- Other income, % of PBT
- 6.6%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹696 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 22.1%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹187 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 35.5%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 58.0%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.3%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹113 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 76.6%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹4.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.3%
Solvency and efficiency
- Current ratio
- 4.58
- Debt / Equity
- 0.01
- Debt / Assets
- 0.01
- Debt / EBITDA
- 0.03
- Interest coverage
- 35.20
- Financial leverage
- 1.13
- CFO / Net profit
- 0.95
- Cash / Market cap
- 6.7%
- Cash per share
- ₹49.66
- Asset turnover
- 0.62
- Fixed asset turnover
- 1.84
- Capital intensity
- 0.54
- Debtor days
- 71 days
- Inventory turnover
- 2.61
- Cash conversion cycle
- 114 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹27 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹435 Cr |
| Sales | Operating profit | ₹261 Cr |
| Operating profit | Interest | ₹2 Cr |
| Operating profit | Depreciation | ₹20 Cr |
| Operating profit | Profit before tax | ₹239 Cr |
| Other income | Profit before tax | ₹10 Cr |
| Profit before tax | Tax and other | ₹60 Cr |
| Profit before tax | Net profit | ₹188 Cr |
Revenue and net profit
Revenue grew 22.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹391 Cr | ₹124 Cr |
| FY2022 | ₹530 Cr | ₹152 Cr |
| FY2023 | ₹461 Cr | ₹90 Cr |
| FY2024 | ₹570 Cr | ₹119 Cr |
| FY2025 | ₹696 Cr | ₹188 Cr |
Cash flows
FY2025: ₹165 Cr from operations, ₹13.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹76 Cr | ₹29 Cr |
| FY2022 | ₹49 Cr | -₹11 Cr |
| FY2023 | ₹64 Cr | -₹60 Cr |
| FY2024 | ₹113 Cr | -₹61 Cr |
| FY2025 | ₹165 Cr | ₹13 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹696 Cr+22.1%1Y
- Net profit
- ₹188 Cr+58.0%1Y
- Cash from operations
- ₹165 Cr
- Free cash flow
- ₹13 Cr
- Revenue CAGR, 5Y
- 12.8%
- EBITDA CAGR, 5Y
- 11.4%
- Net profit CAGR, 5Y
- 10.3%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹696 Cr | ₹261 Cr | — | ₹188 Cr | ₹165 Cr | ₹13 Cr | 18.9% | +22.1% | +58.0% |
Monthly returns
Month-by-month returns of SUPRIYA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,112 Cr |
| Equity capital | ₹16 Cr |
| Reserves | ₹981 Cr |
| Borrowings | ₹5 Cr |
| Other liabilities | ₹110 Cr |
| Assets | ₹1,112 Cr |
| Fixed assets | ₹453 Cr |
| Capital work in progress | ₹148 Cr |
| Investments | ₹63 Cr |
| Other assets | ₹448 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
SUPRIYA trades at 32.6x earnings against a peer median of 52.6x (a 38% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Supriya Lifescience LimitedSUPRIYAthis companyP/E ↓ discount | ₹5,938 Cr | 32.6x | 5.5x | 14.6% | 31.4x |
| Akums Drugs and Pharmaceuticals LimitedAKUMS | ₹6,983 Cr | 50.9x | 2.9x | -114.6% | -133.2x |
| Aarti Pharmalabs LimitedAARTIPHARM | ₹6,923 Cr | 28.3x | 3.6x | 12.4% | 19.5x |
| PARK MEDI WORLD LIMITEDPARKHOSPS | ₹6,504 Cr | 906.0x | — | 7.0% | 214.8x |
| FDC Ltd.FDC | ₹6,387 Cr | 27.0x | 2.6x | 14.6% | 14.2x |
| YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITEDYATHARTH | ₹6,186 Cr | 67.3x | 3.9x | 10.0% | 45.5x |
| Kovai Medical Center & Hospital LtdKOVAI | ₹6,071 Cr | 26.6x | 5.1x | 20.2% | 17.2x |
| Shilpa Medicare Ltd.SHILPAMED | ₹5,771 Cr | 52.6x | 2.2x | 1.3% | 53.7x |
| Entero Healthcare Solutions LimitedENTERO | ₹5,316 Cr | 124.0x | 3.2x | 2.3% | 89.2x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
SUPRIYA since 1 January, against earlier years.
Historical volatility
SUPRIYA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 44.0% |
| FY2022 | 40.0% |
| FY2023 | 28.0% |
| FY2024 | 31.0% |
| FY2025 | 37.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹696 Cr |
| Costs | |
| Interest | ₹2 Cr |
| Expenses | ₹436 Cr |
| Operating profitOperating Profit | ₹261 Cr |
| Other income and charges | |
| Profit before tax | ₹248 Cr |
| Tax | |
| Net profitNet Profit | ₹188 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,112 Cr |
| Equity capitalEquity Capital | ₹16 Cr |
| Reserves | ₹981 Cr |
| Borrowings | ₹5 Cr |
| Other liabilitiesOther Liabilities | ₹110 Cr |
| AssetsTotal Assets | ₹1,112 Cr |
| Fixed assetsFixed Assets | ₹453 Cr |
| Capital work in progressCWIP | ₹148 Cr |
| Investments | ₹63 Cr |
| Other assetsOther Assets | ₹448 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹165 Cr |
| Investing cash flowCash from Investing Activity | -₹152 Cr |
| Financing cash flowCash from Financing Activity | -₹8 Cr |
| Change in cashNet Cash Flow | ₹4 Cr |
Learn while you research
Academy chapters picked for Supriya Lifescience Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 32.6, learn when high multiples are justified.6 min read
- 04 Growth Investing22% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read